Exploratory post hoc analysis of phase 2b/3 trials (induction: 1,021 Crohn's, 1,097 UC patients): upadacitinib benefit vs placebo was consistent across CV risk, prior treatment failure and age subgroups; herpes zoster and serious infections were numerically higher in Crohn's.
Secondary analysisn = 2,118
Vermeire et al. Benefit-risk profile of upadacitinib: exploratory post hoc analysis of phase 2b/3 studies in patients with moderately to severely active ulcerative colitis or Crohn's disease